Jamjoom Pharmaceuticals Factory Co.
Chief Executive Officer · Since Jan 1, 2021
Head of Business Development & Strategy and IR Director
Chief Executive Officer
Head of Manufacturing Operations
General Manager of Sales in Egypt and North Africa
Chief Financial Officer · Since Jan 1, 2013
General Manager Gulf, Levant & other Export Markets · Since Jan 5, 2025
General Manager Consumer Health Division
Global Manufacturing Officer · Since Apr 14, 2024
Head of Operations · Since Jan 1, 2021
Vice President KSA · Since Jan 1, 2025
General Manager Cardiometabolic & CNS · Since Feb 2, 2025
Corporate Human Resources Director · Since Jan 1, 2024
Chief Transformation & Marketing Officer · Since Jan 1, 2025
Sr. Director Business Development · Since Mar 19, 2024
Head of Legal Department · Since Jan 1, 2022
Board Secretary
Notice of Annual General Assembly Meeting - March 2026
Feb 18, 2026
Board of Directors Approves Final Dividend for 2025 Financial Year
Feb 16, 2026
Jamjoom Pharmaceuticals Factory Co. Announces 2025 Full Year Financial Results
Feb 15, 2026
Jamjoom Pharmaceuticals Q4 2025 Interim Results
Jan 20, 2026
Appointment of New Independent Board Member
Dec 10, 2025
Material Supply Agreement with Regional Pharmaceutical Distributor
Nov 5, 2025
Interim Dividend Distribution for H1 2025
Aug 22, 2025
Half Year Financial Results - H1 2025
Aug 20, 2025
TDWL Regulatory Compliance Filing - Corporate Governance Report
Jul 15, 2025
Related Party Transaction Disclosure - Supply Contract with Affiliate
Jun 10, 2025
See Data Freshness Monitor for platform-wide data quality.
Moderate
8-factor live score
10/100
62/100
Caution: M-Score elevated
SouqData provides data for informational purposes only. This does not constitute financial advice, a personal recommendation, or an offer to buy or sell any security. Information may contain errors or be outdated. Always verify data independently and consult a licensed financial adviser before making investment decisions.
Get unlimited access to 180+ insight pages, AI copilot, deep research reports, watchlists, portfolio tracking, and the full 210-column screener across 11 MENA exchanges.
| Company | Market cap (USD) | Dividend yield | Governance | Shariah |
|---|---|---|---|---|
| Jamjoom Pharmaceuticals Factory Co. (4015) | $748M | — | 45(D) | — |
| Dallah Healthcare Co. (4004 · TDWL) | $972M | — | 24(F) | — |
| Astra Industrial Group (1212 · TDWL) | $868M | — | 27(F) | — |
| Dr. Soliman Abdul Kader Fakeeh Hospital Co. (4017 · TDWL) | $561M | — | 24(F) | — |
| National Medical Care Co. (4005 · TDWL) | $446M | — | 15(F) | — |
| Almoosa Health Co. (4018 · TDWL) | $427M | — | 24(F) | — |
Auto-generated peer set — same GICS sector, comparable market-cap band. Governance score is the unified 8-factor model (independence, board size, CEO/chair separation, attendance, auditor, credentials, committees, pay transparency). Shariah uses AAOIFI Standard No. 21. View all 58 sector peers.
